Opinion|Videos|July 1, 2024
Future Directions for Imaging and Biopsy in Prostate Cancer
The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What clinical challenges and unmet needsremain regarding biopsy options in the diagnosis and management of patients with prostate cancer?
- What’s next? Are there any emerging technologies or data that you’re excited about in this area? Is there a role for fusion-guided biopsy with PSMA PET imaging in prostate cancer?
- Please share any closing thoughts or key takeaways regarding the use of fusion-guidedbiopsy in the diagnosis and management of prostate cancer?
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5